Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSL ( (AU:CSL) ) has issued an announcement.
CSL Limited has announced an update on its ongoing on-market buy-back program, revealing that a total of 2,139,429 ordinary fully paid securities have been bought back to date, with an additional 46,154 securities purchased on the previous day. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting a positive outlook on the company’s financial health and market positioning.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of innovative medicines and vaccines. The company is known for its contributions to the healthcare sector, particularly in the areas of immunology, hematology, and influenza vaccines.
Average Trading Volume: 1,320,912
Technical Sentiment Signal: Sell
Current Market Cap: A$87.54B
Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.